Wulff Hansen & CO. Lowers Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Wulff Hansen & CO. cut its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 10.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,647 shares of the company’s stock after selling 1,655 shares during the period. Wulff Hansen & CO.’s holdings in Fresenius Medical Care were worth $332,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Venturi Wealth Management LLC grew its position in Fresenius Medical Care by 8.4% in the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock valued at $129,000 after buying an additional 441 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Fresenius Medical Care by 5.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,278 shares of the company’s stock valued at $210,000 after buying an additional 442 shares during the last quarter. MML Investors Services LLC grew its position in Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after buying an additional 753 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after buying an additional 806 shares during the last quarter. Finally, DAVENPORT & Co LLC grew its position in Fresenius Medical Care by 1.5% in the 4th quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company’s stock valued at $1,316,000 after buying an additional 862 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial raised their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th. Finally, StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th.

Fresenius Medical Care Price Performance

Fresenius Medical Care stock opened at $24.45 on Wednesday. The company has a market cap of $14.35 billion, a P/E ratio of 20.20, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. Fresenius Medical Care AG has a one year low of $17.93 and a one year high of $25.25. The business has a fifty day moving average of $23.73 and a two-hundred day moving average of $22.28.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.